Targeted Genetics
Executive Summary
Will sponsor the gene therapy protocol using autologous CD8+ HIV-specific T cells for the treatment of HIV seropositive individuals approved by the NIH RAC on Sept. 9, not Immunex as stated in the Sept. 13 issue of "The Pink Sheet" (p. 13). Targeted Genetics was spun off by Immunex, becoming an independent entity in 1992.